Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B B Hasinoff

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Anti-Cancer Drugs|July 11, 1998
The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase IIB B Hasinoff, T I Kuschak, C L Fattman, et al.
Biochemical Pharmacology|August 23, 1996
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cellsC L Fattman, W P Allan, B B Hasinoff, et al.
Annals of Internal Medicine|December 15, 1992
Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidismN R Campbell, B B Hasinoff, H Stalts, et al.
British Journal of Clinical Pharmacology|October 1, 1990
Sinemet-ferrous sulphate interaction in patients with Parkinson's diseaseN R Campbell, D Rankine, A E Goodridge, et al.
Anti-Cancer Drugs|April 9, 1999
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesisB B Hasinoff, G L Chee, P Thampatty, et al.
British Journal of Clinical Pharmacology|January 1, 1992
Norfloxacin interaction with antacids and mineralsN R Campbell, M Kara, B B Hasinoff, et al.
Journal of Molecular and Cellular Cardiology|September 23, 1997
Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complexE H Herman, J Zhang, B B Hasinoff, et al.
Molecular and Cellular Biochemistry|August 17, 1999
Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathyN Iliskovic, B B Hasinoff, K L Malisza, et al.
Molecular Pharmacology|February 17, 2001
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cellsB B Hasinoff, M E Abram, N Barnabé, et al.
Molecular Pharmacology|November 14, 1997
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding siteB B Hasinoff, A M Creighton, H Kozlowska, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Anti-Cancer Drugs|July 11, 1998
The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase IIB B Hasinoff, T I Kuschak, C L Fattman, et al.
Biochemical Pharmacology|August 23, 1996
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cellsC L Fattman, W P Allan, B B Hasinoff, et al.
Annals of Internal Medicine|December 15, 1992
Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidismN R Campbell, B B Hasinoff, H Stalts, et al.
British Journal of Clinical Pharmacology|October 1, 1990
Sinemet-ferrous sulphate interaction in patients with Parkinson's diseaseN R Campbell, D Rankine, A E Goodridge, et al.
Anti-Cancer Drugs|April 9, 1999
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesisB B Hasinoff, G L Chee, P Thampatty, et al.
British Journal of Clinical Pharmacology|January 1, 1992
Norfloxacin interaction with antacids and mineralsN R Campbell, M Kara, B B Hasinoff, et al.
Journal of Molecular and Cellular Cardiology|September 23, 1997
Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complexE H Herman, J Zhang, B B Hasinoff, et al.
Molecular and Cellular Biochemistry|August 17, 1999
Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathyN Iliskovic, B B Hasinoff, K L Malisza, et al.
Molecular Pharmacology|February 17, 2001
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cellsB B Hasinoff, M E Abram, N Barnabé, et al.
Molecular Pharmacology|November 14, 1997
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding siteB B Hasinoff, A M Creighton, H Kozlowska, et al.
Pageof 9